同步放化疗与序贯放化疗治疗67例局部晚期非小细胞肺癌的疗效比较  

A Comparasion of Response between Concurrent Chemoradiotherapy and Sequential Chemoradiotherapy for 67 Cases with Locally Advanced Non-small Cell Lung Cancer

作　　者：韩国平[1] 李刚[1] 吕桂泉[1] 

机构地区：[1]浙江萧山医院,浙江杭州311201

出　　处：《肿瘤学杂志》2010年第12期934-937,共4页Journal of Chinese Oncology

摘　　要：[目的]探讨同步放化疗及序贯放化疗治疗局部晚期非小细胞肺癌(NSCLC)的疗效及不良反应。[方法]67例局部晚期NSCLC患者分为同步放化疗组(35例)及序贯放化疗组(32例)。同步放化疗组采用紫杉醇40mg/m2,卡铂AUC=2,d1;3DCRT与化疗同时开始,每周1次。序贯放化疗组先行2个周期全身化疗:紫杉醇150mg/m2,卡铂AUC=6,d1,21d为1个周期;第42d开始行3DCRT。[结果]同步放化疗组及序贯放化疗组有效率分别为77%及56%,1年生存率分别为76%和66%,2年生存率分别为39%和32%,差异均无统计学意义(P>0.05)。两组不良反应差异无显著性(P>0.05)。同步放化疗组、序贯放化疗组局部复发率分别为20%(7/35)和31%(10/32),差异有统计学意义(χ2=4.521,P=0.033)。[结论]同步放化疗治疗局部晚期NSCLC疗效较好,但有增加不良反应的可能。[Purpose] To investigate the response and toxicity of concurrent chemoradiotherapy and sequential chemoradiotherapy for NSCLC. [Methods] Sixty-seven cases with locally advanced NSCLC were divided into concurrent chemoradiotherapy（CC） group（n=35） and sequential chemora- diotherapy （SC） group （n=32）. Patients in CC group received paclitaxel 40mg/m2 and carboplatin AUC=2, d1, and 3DCRT was begun at d1, once a week. Patients in SC group received 2 cycles chemotherapy before 3DCRT, chemotherapy with paclitaxel 150mg/m2 and carboplatin AUC=6, 21 days as a cycle, and 3DCRT was begun at d42. [Results] The overall response rate in CC group and SC group was 77% and 56%, 1-year survival rate was 76% and 66%, 2-year survival rate was 39% and 32% respectively, without significant difference （P 0.05）. Toxicity between the two groups had no significant difference （P0.05）. The local recurrence rate in CC group and SC group was 20% （7/35） and 31% （10/32）, with significant difference （χ2=4.521, P=0.033）. [Conclusion] Concurrent chemoradiotherapy for locally advanced NSCLC is effective, but it may increase toxicity.

关 键 词：癌 非小细胞肺 三维适形放疗 药物疗法 

分 类 号：R734.2[医药卫生—肿瘤]